Edition:
India

Axovant Sciences Ltd (AXON.OQ)

AXON.OQ on NASDAQ Stock Exchange Global Select Market

2.03USD
19 Jan 2018
Change (% chg)

$-0.03 (-1.46%)
Prev Close
$2.06
Open
$2.05
Day's High
$2.06
Day's Low
$2.00
Volume
129,478
Avg. Vol
506,052
52-wk High
$27.93
52-wk Low
$2.00

Latest Key Developments (Source: Significant Developments)

BRIEF-Axovant Sciences Submitted Final Protocol With Statistical Analysis Plan To FDA For Dementia With Lewy Bodies Study
Thursday, 7 Dec 2017 

Corrects headline to say the final protocol was submitted for dementia with Lewy bodies study, not Parkinson's study:AXOVANT SCIENCES - SUBMITTED FINAL PROTOCOL WITH STATISTICAL ANALYSIS PLAN TO FDA DESIGNATES UNIFIED PARKINSON DISEASE RATING SCALE - PART III AS PRIMARY EFFICACY ENDPOINT.AXOVANT SCIENCES LTD SAYS SUBMITTED PROTOCOL THAT DESIGNATES ADAS-COG & CIBIC+ AS CO-SECONDARY ENDPOINTS FOR PHASE 2B HEADWAY STUDY - SEC FILING.  Full Article

Axovant announces second fiscal quarter results
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Axovant Sciences Ltd :Axovant announces second fiscal quarter financial results and corporate updates.Q2 loss per share $0.64.Q2 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.Axovant Sciences Ltd - ‍Axovant held cash of $235.4 million at september 30, 2017​.  Full Article

Axovant sciences says exploring nelotanserin as treatment for Rem sleep behavior disorder
Monday, 13 Feb 2017 

Axovant Sciences Ltd : Axovant sciences announces preliminary results from interim analysis of phase 2 study testing investigational drug nelotanserin in Lewy body dementia patients . Axovant expects to initiate phase 3 program in second half of 2017 . Plans to expand study recruitment to further explore updrs findings and expects final results in mid-2017 . Axovant Sciences-in interim analysis, secondary endpoints did not demonstrate statistically significant differences for nelotanserin relative to placebo .Axovant Sciences-is exploring nelotanserin as a potential treatment for rem sleep behavior disorder (RBD) in patients with dementia with Lewy bodies.  Full Article

Axovant Sciences receives FDA fast-track designation for intepirdine
Monday, 26 Sep 2016 

Axovant Sciences Ltd :Axovant Sciences receives FDA fast-track designation for intepirdine as an investigational treatment for dementia with lewy bodies.  Full Article

Axovant Sciences posts Q1 loss per share of $0.38
Tuesday, 16 Aug 2016 

Axovant Sciences Ltd : Axovant sciences announces expansion of dementia pipeline and reports financial results for the first fiscal quarter ended June 30, 2016 . Q1 loss per share $0.38 . Q1 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S . Axovant says Axovant and QAAM Pharmaceuticals (QAAM) have entered into an exclusive license agreement . Axovant says financial terms of transaction were not disclosed . Axovant plans to initiate clinical studies for RVT-103 shortly, with initial results expected in 2017 . Announces plan to develop RVT-103, a combination of Glycopyrrolate and Donepezil, as a potential treatment for patients with dementia .Axovant sciences ltd says axovant does not expect program to have a material effect on its use of cash in fiscal year ending March 31, 2017.  Full Article

Axovant Q4 loss per share $0.30
Monday, 6 Jun 2016 

Axovant Sciences : Q4 loss per share $0.30 .Q4 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S.  Full Article

Axovant shares plunge after key drug program scrapped

Axovant Sciences Ltd's shares fell nearly 50 percent on Monday after the company scrapped its intepirdine program following the failure of its lead experimental treatment in a mid-stage study on patients suffering from a type of dementia.